DAPTEV: Deep aptamer evolutionary modelling for COVID-19 drug design.
Ontology highlight
ABSTRACT:
SUBMITTER: Andress C
PROVIDER: S-EPMC10351721 | biostudies-literature | 2023 Jul
REPOSITORIES: biostudies-literature
Publications
DAPTEV: Deep aptamer evolutionary modelling for COVID-19 drug design.
Andress Cameron C Kappel Kalli K Villena Marcus Elbert ME Cuperlovic-Culf Miroslava M Yan Hongbin H Li Yifeng Y
PLoS computational biology 20230705 7
Typical drug discovery and development processes are costly, time consuming and often biased by expert opinion. Aptamers are short, single-stranded oligonucleotides (RNA/DNA) that bind to target proteins and other types of biomolecules. Compared with small-molecule drugs, aptamers can bind to their targets with high affinity (binding strength) and specificity (uniquely interacting with the target only). The conventional development process for aptamers utilizes a manual process known as Systemat ...[more]
Similar Datasets
Project description:The worldwide coronavirus (COVID-19) pandemic made dramatic and rapid progress in the year 2020 and requires urgent global effort to accelerate the development of a vaccine to stop the daily infections and deaths. Several types of vaccine have been designed to teach the immune system how to fight off certain kinds of pathogens. mRNA vaccines are the most important candidate vaccines because of their capacity for rapid development, high potency, safe administration and potential for low-cost manufacture. mRNA vaccine acts by training the body to recognize and response to the proteins produced by disease-causing organisms such as viruses or bacteria. This type of vaccine is the fastest candidate to treat COVID-19 but it currently facing several limitations. In particular, it is a challenge to design stable mRNA molecules because of the inefficient in vivo delivery of mRNA, its tendency for spontaneous degradation and low protein expression levels. This work designed and implemented a sequence deep model based on bidirectional GRU and LSTM models applied on the Stanford COVID-19 mRNA vaccine dataset to predict the mRNA sequences responsible for degradation by predicting five reactivity values for every position in the sequence. Four of these values determine the likelihood of degradation with/without magnesium at high pH (pH 10) and high temperature (50 degrees Celsius) and the fifth reactivity value is used to determine the likely secondary structure of the RNA sample. The model relies on two types of features, namely numerical and categorical features, where the categorical features are extracted from the mRNA sequences, structure and predicted loop. These features are represented and encoded by numbers, and then, the features are extracted using embedding layer learning. There are five numerical features depending on the likelihood for each pair of nucleotides in the RNA. The model gives promising results because it predicts the five reactivity values with a validation mean columnwise root mean square error (MCRMSE) of 0.125 using LSTM model with augmentation and the codon encoding method. Codon encoding outperforms Base encoding in MCRMSE validation error using the LSTM model meanwhile Base encoding outperforms codon encoding due to less over-fitting and the difference between the training and validation loss error is 0.008.
| S-EPMC8237341 | biostudies-literature
Project description:COVID-19 or SARS-Cov-2, affecting 6 million people and more than 300,000 deaths, the global pandemic has engulfed more than 90% countries of the world. The virus started from a single organism and is escalating at a rate of 3% to 5% daily and seems to be a never ending process. Understanding the basic dynamics and presenting new predictions models for evaluating the potential effect of the virus is highly crucial. In present work, an evolutionary data analytics method called as Genetic programming (GP) is used to mathematically model the potential effect of coronavirus in 15 most affected countries of the world. Two datasets namely confirmed cases (CC) and death cases (DC) were taken into consideration to estimate, how transmission varied in these countries between January 2020 and May 2020. Further, a percentage rise in the number of daily cases is also shown till 8 June 2020 and it is expected that Brazil will have the maximum rise in CC and USA have the most DC. Also, prediction of number of new CC and DC cases for every one million people in each of these countries is presented. The proposed model predicted that the transmission of COVID-19 in China is declining since late March 2020; in Singapore, France, Italy, Germany and Spain the curve has stagnated; in case of Canada, South Africa, Iran and Turkey the number of cases are rising slowly; whereas for USA, UK, Brazil, Russia and Mexico the rate of increase is very high and control measures need to be taken to stop the chains of transmission. Apart from that, the proposed prediction models are simple mathematical equations and future predictions can be drawn from these general equations. From the experimental results and statistical validation, it can be said that the proposed models use simple linkage functions and provide highly reliable results for time series prediction of COVID-19 in these countries.
| S-EPMC7367045 | biostudies-literature
Project description:BackgroundIn 2003, the first case of severe acute respiratory syndrome coronavirus (SARS-CoV) was recorded. Coronaviruses (CoVs) have caused a major outbreak of human fatal pneumonia. Currently, there is no specific drug or treatment for diseases caused by SARS CoV 2. Computational approach that adopts dynamic models is widely accepted as indispensable tool in drug design but yet to be exploited in covid-19 in Zaria, Nigeria. In this study, steps were taken to advance on the successful achievements in the field of covid-19 drug, with the aid of in silico drug design technique, to create novel inhibitor drug candidates with better activity. In this study, one thousand human immunodeficiency virus (HIV1) antiviral chemical compounds from www.bindingBD.org were docked on the SARS CoV 2 main protease protein data bank identification number 6XBH (PDB ID: 6XBH) and the molecular docking score were ranked in order to identify the compounds with the highest inhibitory effects, and easy selection for future studies.ResultsThe docking studies showed some interesting results. Inhibitors with Index numbers 331, 741, and 819 had the highest binding affinity. Similarly, inhibitors with Index number 441, 847, and 46 had the lowest hydrogen bond energy. Inhibitor with index number 331 was reported with the lowest value (- 48.38kCal/mol). Five new compounds were designed from the selected six (6) compounds with the best binding score giving a total of thirty (30) novel compounds. The low binding energy of inhibitor with index no. 847b is unique, as most of the interaction energies are of H-bond type with amino acids (Thr26, Gly143, Ser144, Cys145, Glu166, Gln189, Hie164, Met49, Thr26, Thr25, Thr190, Asn142, Met165) resulting in an overall negative value (-16.31 kCal/mol) making it the best of all the newly designed inhibitors.ConclusionsThe novel inhibitor is 2-(2-(5-amino-2-((((3-aminobenzyl)oxy)carbonyl)amino)-5-oxopentanamido)-4-(2-(tert-butyl)-4-oxo-4-(pentan-3-ylamino) butanamido)-3-hydroxybutyl) benzoic acid. The improvement it has over the parent inhibitor is from the primary amine group attached to meta position of first benzene ring and the carboxyl group attached to the ortho position of the second benzene ring. The molecular dynamics studies also show that the novel inhibitor remains stable after the study. This result makes it a better drug candidate against SARS CoV 2 main protease when compared with the co-crystallized inhibitor or any of the 1000 docked inhibitors.Supplementary informationThe online version contains supplementary material available at 10.1186/s42269-022-00892-z.
| S-EPMC9284480 | biostudies-literature
Project description:Vaccines have made gratifying progress in preventing the 2019 coronavirus disease (COVID-19) pandemic. However, the emergence of variants, especially the latest delta variant, has brought considerable challenges to human health. Hence, the development of robust therapeutic approaches, such as anti-COVID-19 drug design, could aid in managing the pandemic more efficiently. Some drug design strategies have been successfully applied during the COVID-19 pandemic to create and validate related lead drugs. The computational drug design methods used for COVID-19 can be roughly divided into (i) structure-based approaches and (ii) artificial intelligence (AI)-based approaches. Structure-based approaches investigate different molecular fragments and functional groups through lead drugs and apply relevant tools to produce antiviral drugs. AI-based approaches usually use end-to-end learning to explore a larger biochemical space to design antiviral drugs. This review provides an overview of the two design strategies of anti-COVID-19 drugs, the advantages and disadvantages of these strategies and discussions of future developments.
| S-EPMC8690229 | biostudies-literature
Project description:Radiological methodologies, such as chest x-rays and CT, are widely employed to help diagnose and monitor COVID-19 disease. COVID-19 displays certain radiological patterns easily detectable by X-rays of the chest. Therefore, radiologists can investigate these patterns for detecting coronavirus disease. However, this task is time-consuming and needs lots of trial and error. One of the main solutions to resolve this issue is to apply intelligent techniques such as deep learning (DL) models to automatically analyze the chest X-rays. Nevertheless, fine-tuning of architecture and hyperparameters of DL models is a complex and time-consuming procedure. In this paper, we propose an effective method to detect COVID-19 disease by applying convolutional neural network (CNN) to the chest X-ray images. To improve the accuracy of the proposed method, the last Softmax CNN layer is replaced with a K -nearest neighbors (KNN) classifier which takes into account the agreement of the neighborhood labeling. Moreover, we develop a novel evolutionary algorithm by improving the basic version of competitive swarm optimizer. To this end, three powerful evolutionary operators: Cauchy Mutation (CM), Evolutionary Boundary Constraint Handling (EBCH), and tent chaotic map are incorporated into the search process of the proposed evolutionary algorithm to speed up its convergence and make an excellent balance between exploration and exploitation phases. Then, the proposed evolutionary algorithm is used to automatically achieve the optimal values of CNN's hyperparameters leading to a significant improvement in the classification accuracy of the proposed method. Comprehensive comparative results reveal that compared with current models in the literature, the proposed method performs significantly more efficient.
| S-EPMC8966159 | biostudies-literature
Project description:Topic modelling with innovative deep learning methods has gained interest for a wide range of applications that includes COVID-19. It can provide, psychological, social and cultural insights for understanding human behaviour in extreme events such as the COVID-19 pandemic. In this paper, we use prominent deep learning-based language models for COVID-19 topic modelling taking into account data from the emergence (Alpha) to the Omicron variant in India. Our results show that the topics extracted for the subsequent waves had certain overlapping themes such as governance, vaccination, and pandemic management while novel issues aroused in political, social and economic situations during the COVID-19 pandemic. We also find a strong correlation between the major topics with news media prevalent during the respective time period. Hence, our framework has the potential to capture major issues arising during different phases of the COVID-19 pandemic which can be extended to other countries and regions.
| S-EPMC10393149 | biostudies-literature
Project description:AimWe hypothesized that viral kinetic modelling could be helpful to prioritize rational drug combinations for COVID-19. The aim of this research was to use a viral cell cycle model of SARS-CoV-2 to explore the potential impact drugs, or combinations of drugs, that act at different stages in the viral life cycle might have on various metrics of infection outcome relevant in the early stages of COVID-19 disease.MethodsUsing a target-cell limited model structure that has been used to characterize viral load dynamics from COVID-19 patients, we performed simulations to inform on the combinations of therapeutics targeting specific rate constants. The endpoints and metrics included viral load area under the curve (AUC), duration of viral shedding and epithelial cells infected. Based on the known kinetics of the SARS-CoV-2 life cycle, we rank ordered potential targeted approaches involving repurposed, low-potency agents.ResultsOur simulations suggest that targeting multiple points central to viral replication within infected host cells or release from those cells is a viable strategy for reducing both viral load and host cell infection. In addition, we observed that the time-window opportunity for a therapeutic intervention to effect duration of viral shedding exceeds the effect on sparing epithelial cells from infection or impact on viral load AUC. Furthermore, the impact on reduction on duration of shedding may extend further in patients who exhibit a prolonged shedder phenotype.ConclusionsOur work highlights the use of model-informed drug repurposing approaches to better rationalize effective treatments for COVID-19.
| S-EPMC8451752 | biostudies-literature
Project description:Effective treatments for COVID-19 are urgently needed. However, discovering single-agent therapies with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been challenging. Combination therapies play an important role in antiviral therapies, due to their improved efficacy and reduced toxicity. Recent approaches have applied deep learning to identify synergistic drug combinations for diseases with vast preexisting datasets, but these are not applicable to new diseases with limited combination data, such as COVID-19. Given that drug synergy often occurs through inhibition of discrete biological targets, here we propose a neural network architecture that jointly learns drug-target interaction and drug-drug synergy. The model consists of two parts: a drug-target interaction module and a target-disease association module. This design enables the model to utilize drug-target interaction data and single-agent antiviral activity data, in addition to available drug-drug combination datasets, which may be small in nature. By incorporating additional biological information, our model performs significantly better in synergy prediction accuracy than previous methods with limited drug combination training data. We empirically validated our model predictions and discovered two drug combinations, remdesivir and reserpine as well as remdesivir and IQ-1S, which display strong antiviral SARS-CoV-2 synergy in vitro. Our approach, which was applied here to address the urgent threat of COVID-19, can be readily extended to other diseases for which a dearth of chemical-chemical combination data exists.
| S-EPMC8488647 | biostudies-literature
Project description:The recent covid crisis has provided important lessons for academia and industry regarding digital reorganization. Among the fascinating lessons from these times is the huge potential of data analytics and artificial intelligence. The crisis exponentially accelerated the adoption of analytics and artificial intelligence, and this momentum is predicted to continue into the 2020s and beyond. Drug development is a costly and time-consuming business, and only a minority of approved drugs generate returns exceeding the research and development costs. As a result, there is a huge drive to make drug discovery cheaper and faster. With modern algorithms and hardware, it is not too surprising that the new technologies of artificial intelligence and other computational simulation tools can help drug developers. In only two years of covid research, many novel molecules have been designed/identified using artificial intelligence methods with astonishing results in terms of time and effectiveness. This paper reviews the most significant research on artificial intelligence in de novo drug design for COVID-19 pharmaceutical research.
| S-EPMC8949797 | biostudies-literature
Project description:This is an analysis of the COVID-19 pandemic by comparably simple mathematical and numerical methods. The final goal is to predict the peak of the epidemic outbreak per country with a reliable technique. The difference to other modelling approaches is to stay extremely close to the available data, using as few hypotheses and parameters as possible. For the convenience of readers, the basic notions of modelling epidemics are collected first, focusing on the standard SIR model. Proofs of various properties of the model are included. But such models are not directly compatible with available data. Therefore a special variation of a SIR model is presented that directly works with the data provided by the Johns Hopkins University. It allows to monitor the registered part of the pandemic, but is unable to deal with the hidden part. To reconstruct data for the unregistered Infected, a second model uses current experimental values of the infection fatality rate and a data-driven estimation of a specific form of the recovery rate. All other ingredients are data-driven as well. This model allows predictions of infection peaks. Various examples of predictions are provided for illustration. They show what countries have to face that are still expecting their infection peak. Running the model on earlier data shows how closely the predictions follow the transition from an uncontrolled outbreak to the mitigation situation by non-pharmaceutical interventions like contact restrictions. Supplementary Information The online version of this article (10.1365/s13291-020-00219-9) contains supplementary material, which is available to authorized users.
| S-EPMC7322402 | biostudies-literature